Category Archives: Global News Feed


Stem Cell Clinic > Global News Feed

MacroGenics and EVERSANA Announce Agreement to Support the Potential Launch and Commercialization of Margetuximab

By Global News Feed

ROCKVILLE, MD and CHICAGO, IL, Nov. 30, 2020 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it has partnered with EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, to commercialize margetuximab in the United States, if approved.

Continue reading here:
MacroGenics and EVERSANA Announce Agreement to Support the Potential Launch and Commercialization of Margetuximab

Sanofi: Information concerning the total number of voting rights and shares – October 2020

By Global News Feed

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

Here is the original post:
Sanofi: Information concerning the total number of voting rights and shares - October 2020

Braingrid Limited Announces Proposed Change of Business to an Investment Company and Proposed Name Change

By Global News Feed

TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Braingrid Limited (CSE: BGRD) (“Braingrid” or the “Company”) is pleased to announce that it will be pursuing a change of business to an investment company (the “Proposed COB”) under the rules of the Canadian Securities Exchange (the “CSE”).

See original here:
Braingrid Limited Announces Proposed Change of Business to an Investment Company and Proposed Name Change

Junshi Biosciences Announces Acceptance by NMPA of its IND Application for JS006

By Global News Feed

SHANGHAI, China, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, is pleased to announce that the China National Medical Products Administration (NMPA) has recently accepted its Investigational New Drug (IND) application for JS006, a humanized monoclonal antibody against a human lymphocyte inhibitory receptor TIGIT.

Go here to see the original:
Junshi Biosciences Announces Acceptance by NMPA of its IND Application for JS006

Tower One Announces Third Quarter 2020 Results and Provides an Update on the Progress of the Business

By Global News Feed

VANCOUVER, British Columbia, Nov. 30, 2020 (GLOBE NEWSWIRE) -- TOWER ONE WIRELESS CORP. (CSE: TO) (OTCQB: TOWTF) (Frankfurt: 1P3N) (“Tower One” or the “Company”) announces that it has filed its financial results for the third quarter of 2020, and the related Management’s Discussion and Analysis, the details of which are available on the System for Electronic Document Analysis and Retrieval at www.sedar.com.

Here is the original post:
Tower One Announces Third Quarter 2020 Results and Provides an Update on the Progress of the Business

Amarin Files Patent Infringement Lawsuit Against Hikma

By Global News Feed

DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), announced today the filing of a patent infringement lawsuit by Amarin affiliates and a licensor against Hikma Pharmaceuticals PLC and Hikma’s U.S. affiliate. The lawsuit was filed in the United States District Court in Delaware. A copy of the complaint is available in the FAQ section of Amarin’s investor relations website.

Read more:
Amarin Files Patent Infringement Lawsuit Against Hikma

Progenity Announces Proposed Public Offering of Common Stock

By Global News Feed

SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it has commenced an underwritten public offering of $25 million of shares of its common stock. In addition, Progenity is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $3.75 million of shares of common stock at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.

Visit link:
Progenity Announces Proposed Public Offering of Common Stock

Progenity Announces Proposed Convertible Senior Notes Offering

By Global News Feed

SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG) today announced its intention to offer, subject to market and other conditions, $75 million aggregate principal amount of convertible senior notes due 2025 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Progenity also expects to grant the initial purchaser of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date notes are first issued, up to an additional $15 million principal amount of notes.

Read more:
Progenity Announces Proposed Convertible Senior Notes Offering

Junshi Biosciences Announces Dosing of First Patient in Phase I Study of Anti-TROP2 Antibody -TUB196 Conjugate

By Global News Feed

SHANGHAI, China, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, is pleased to announce that the Phase I clinical study (NCT04601285) of a recombinant humanized anti-TROP2 monoclonal antibody - Tub196 conjugate (JS108), has completed the dosing of the first patient.

Link:
Junshi Biosciences Announces Dosing of First Patient in Phase I Study of Anti-TROP2 Antibody -TUB196 Conjugate

→←